New drug cocktail aims to tame deadly transplant side effect
NCT ID NCT07238712
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matched donor. The goal is to reduce life-threatening complications and improve overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ruxolitinib and abatacept (Orencia)
- What this could lead to
- If successful, this could reduce serious complications like graft-versus-host disease after transplant, improving survival for patients with high-risk blood cancers.
- What could go wrong
- This is a small, early-phase trial with only 60 participants. The new drug combination may not work better than standard care and could have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pavlov University
RECRUITINGSaint Petersburg, 197022, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a new pill boost the power of an existing leukemia treatment?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- Can a Two-Drug combo tame a rare blood cancer?